Literature DB >> 16585634

Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis.

A E Bryant1,2, C R Bayer1,2, M J Aldape1, R J Wallace2, R W Titball3, D L Stevens4,2.   

Abstract

Clostridium perfringens gas gangrene is a fulminant necrotizing infection in which inflammatory cells are notably absent from infected tissues but are often massed within adjacent vessels. It has been shown that C. perfringens phospholipase C (PLC) stimulates formation of large intravascular platelet/leukocyte complexes and that PLC-induced activation of platelet gpIIbIIIa plays a major role. In vivo, such aggregates contribute to microvascular thrombosis and ischaemic necrosis of tissue. However, the effects of adherent platelets on neutrophil diapedesis have not been established. The present work investigated (1) the contribution of platelet P-selectin (CD62P) to PLC-induced cellular complex formation and (2) the effects of platelet adhesion on neutrophil diapedesis. The effects of anti-gpIIbIIIa and anti-CD62P strategies on PLC-induced complex formation were measured by flow cytometry and followed by light microscopy. Both platelet gpIIbIIIa and CD62P contributed to the formation of platelet/leukocyte complexes. Specifically, gpIIbIIIa mediated the formation of large platelet/platelet aggregates that were tethered to the leukocyte principally via CD62P. Neutrophil diapedesis, quantified by a transendothelial cell migration assay and visualized by electron microscopy, was significantly reduced (>60%) by the adherence of large platelet aggregates. It was concluded that the absence of a tissue inflammatory response in C. perfringens gas gangrene is due, in part, to impaired neutrophil mobility caused by large aggregates of adherent platelets induced by PLC. Further, an adjunctive immunotherapeutic strategy targeting both gpIIbIIIa and CD62P may improve the tissue inflammatory response, prevent vascular occlusion, maintain tissue viability, and reduce the need for radical amputation in patients with clostridial gas gangrene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585634     DOI: 10.1099/jmm.0.46390-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  20 in total

1.  Pathology of fatal traumatic and nontraumatic clostridial gas gangrene: a histopathological, immunohistochemical, and ultrastructural study of six autopsy cases.

Authors:  Michael Tsokos; Sarah Schalinski; Friedrich Paulsen; Jan P Sperhake; Klaus Püschel; Ingo Sobottka
Journal:  Int J Legal Med       Date:  2007-03-17       Impact factor: 2.686

Review 2.  Gas gangrene in mammals: a review.

Authors:  Carlos A Oliveira Junior; Rodrigo O S Silva; Francisco C F Lobato; Mauricio A Navarro; Francisco A Uzal
Journal:  J Vet Diagn Invest       Date:  2020-02-21       Impact factor: 1.279

3.  Clostridial myonecrosis: new insights in pathogenesis and management.

Authors:  Amy E Bryant; Dennis L Stevens
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

4.  Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens.

Authors:  Fatemeh Rafii; Miseon Park; Amy E Bryant; Shemedia J Johnson; Robert D Wagner
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

5.  Staphylococcus aureus α-hemolysin promotes platelet-neutrophil aggregate formation.

Authors:  Tanyalak Parimon; Zhi Li; Devin D Bolz; Eric R McIndoo; Clifford R Bayer; Dennis L Stevens; Amy E Bryant
Journal:  J Infect Dis       Date:  2013-05-22       Impact factor: 5.226

6.  The cysteine protease α-clostripain is not essential for the pathogenesis of Clostridium perfringens-mediated myonecrosis.

Authors:  Anjana Chakravorty; Milena M Awad; Thomas J Hiscox; Jackie K Cheung; Glen P Carter; Jocelyn M Choo; Dena Lyras; Julian I Rood
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

Review 7.  Perfringolysin O: The Underrated Clostridium perfringens Toxin?

Authors:  Stefanie Verherstraeten; Evy Goossens; Bonnie Valgaeren; Bart Pardon; Leen Timbermont; Freddy Haesebrouck; Richard Ducatelle; Piet Deprez; Kristin R Wade; Rodney Tweten; Filip Van Immerseel
Journal:  Toxins (Basel)       Date:  2015-05-14       Impact factor: 4.546

8.  The pore-forming α-toxin from clostridium septicum activates the MAPK pathway in a Ras-c-Raf-dependent and independent manner.

Authors:  Anjana Chakravorty; Milena M Awad; Jackie K Cheung; Thomas J Hiscox; Dena Lyras; Julian I Rood
Journal:  Toxins (Basel)       Date:  2015-02-10       Impact factor: 4.546

9.  Clostridium perfringens α-Toxin Impairs Innate Immunity via Inhibition of Neutrophil Differentiation.

Authors:  Masaya Takehara; Teruhisa Takagishi; Soshi Seike; Kaori Ohtani; Keiko Kobayashi; Kazuaki Miyamoto; Tohru Shimizu; Masahiro Nagahama
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

10.  Molecular and cellular basis of microvascular perfusion deficits induced by Clostridium perfringens and Clostridium septicum.

Authors:  Michael J Hickey; Rain Y Q Kwan; Milena M Awad; Catherine L Kennedy; Lauren F Young; Pam Hall; Leanne M Cordner; Dena Lyras; John J Emmins; Julian I Rood
Journal:  PLoS Pathog       Date:  2008-04-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.